These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37316690)

  • 1. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
    Mease PJ; Hatemi G; Paris M; Cheng S; Maes P; Zhang W; Shi R; Flower A; Picard H; Stein Gold L
    Am J Clin Dermatol; 2023 Sep; 24(5):809-820. PubMed ID: 37316690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
    Mease PJ; Gladman DD; Gomez-Reino JJ; Hall S; Kavanaugh A; Lespessailles E; Schett G; Paris M; Delev N; Teng L; Wollenhaupt J
    ACR Open Rheumatol; 2020 Aug; 2(8):459-470. PubMed ID: 32710493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
    Persson R; Cordey M; Paris M; Jick S
    Drug Saf; 2022 Nov; 45(11):1403-1411. PubMed ID: 36151359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
    Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label studies on apremilast in dermatology: a review.
    Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
    J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
    Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
    Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
    Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
    Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.